SCHEMBL25199143

SCHEMBL25199143

COC(=O)c1cn(S(=O)(=O)c2cccnc2)c(-c2ccccc2F)c1OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
CHRNB4 P30926 2/20 0.41
CHRNA3 P32297 2/20 0.41
CHRNB2 P17787 1/20 0.41
CHRNA4 P43681 1/20 0.41
PIK3CG P48736 1/20 0.40
TSHR P16473 2/20 0.38
HTT P42858 1/20 0.37
MAPK1 P28482 1/20 0.37
POLB P06746 1/20 0.36
KDM4E B2RXH2 5/20 0.36
GABRA1 P14867 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA3 P34903 1/20 0.36
GABRA2 P47869 1/20 0.36
ALDH1A1 P00352 2/20 0.36
LMNA P02545 1/20 0.35
HSD17B10 Q99714 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31019961 1.00 KMT2A (0.43) KMT2AMEN1CHRNB4CHRNA3CHRNB2
SCHEMBL25188299 0.90 POLB (0.44) KMT2AMEN1CHRNB4CHRNA3CHRNB2
SCHEMBL31019969 0.90 POLB (0.44) KMT2AMEN1CHRNB4CHRNA3CHRNB2
SCHEMBL25228488 0.85 KMT2A (0.41) KMT2AMEN1TSHRHTTMAPK1
SCHEMBL31019972 0.85 KMT2A (0.40) KMT2AMEN1CHRNB4CHRNA3CHRNB2
SCHEMBL25187015 0.85 KMT2A (0.40) KMT2AMEN1CHRNB4CHRNA3CHRNB2
SCHEMBL30287347 0.85 KMT2A (0.41) KMT2AMEN1TSHRHTTMAPK1
SCHEMBL31019973 0.82 CHRNB4 (0.37) KMT2ACHRNB4CHRNA3CHRNB2CHRNA4
SCHEMBL25193028 0.82 CHRNB4 (0.37) KMT2ACHRNB4CHRNA3CHRNB2CHRNA4
SCHEMBL24893597 0.82 GPR119 (0.42) KMT2AMEN1CHRNB4CHRNA3PIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250051275-A1 PYRROLE DERIVATIVE OR PHARMACEUTICALLY OR SITOLOGICALLY ACCEPTABLE SALTS THEREOF, AND COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF GASTROINTESTINAL DISORDERS COMPRISING SAME AS ACTIVE INGREDIENT HANA PHARM CO., LTD. (KR) 2025-02-13 US disclosed
EP-4434966-A1 PYRROLE DERIVATIVE OR PHARMACEUTICALLY OR SITOLOGICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF GASTROINTESTINAL DISORDERS COMPRISING SAME AS ACTIVE INGREDIENT Hana Pharm. Co. Ltd. (KR) 2024-09-25 EP disclosed
WO-2023090942-A1 PYRROLE DERIVATIVE OR PHARMACEUTICALLY OR SITOLOGICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF GASTROINTESTINAL DISORDERS COMPRISING SAME AS ACTIVE INGREDIENT 하나제약 주식회사 2023-05-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051275-A1 PYRROLE DERIVATIVE OR PHARMACEUTICALLY OR SITOLOGICALLY ACCEPTABLE SALTS THEREOF, AND COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF GASTROINTESTINAL DISORDERS COMPRISING SAME AS ACTIVE INGREDIENT STOM, SI, PGC KMT2A 528/4885MEN1 1595/4885CHRNB4 4849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.